Clinical Trials on NonSegmental Vitiligo in United Kingdom
Total 72 results
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoUnited States, Spain, Australia, Mexico, Canada, China, Japan, Italy, Turkey, Korea, Republic of, Germany, South Africa, Poland, United Kingdom, Bulgaria
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoChina, Japan, Canada, Spain, United States, Hungary, Poland, Slovakia
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationCompletedNonSegmental VitiligoUnited States, Canada
-
Incyte CorporationActive, not recruitingA Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital VitiligoNonsegmental Vitiligo With Genital InvolvementCanada, United States, France
-
Incyte CorporationRecruitingNonSegmental VitiligoJapan, Spain, United States, Poland, Canada, Belgium, Germany, Netherlands, France, Mexico
-
Chelsea and Westminster NHS Foundation TrustCompleted
-
Momentum DataPfizerActive, not recruiting
-
The Royal Wolverhampton Hospitals NHS TrustIncyte Biosciences International SàrlRecruitingVitiligo | Dermatologic DiseaseUnited Kingdom
-
University of NottinghamCompleted
-
Henry Ford Health SystemTerminatedGeneralized VitiligoUnited States
-
St. Luke's-Roosevelt Hospital CenterBeth Israel Medical CenterCompleted
-
Incyte CorporationCompletedNon-segmental VitiligoUnited States, Canada, Italy, France, Germany, Spain, Poland, Bulgaria, Netherlands
-
Merck Sharp & Dohme LLCRecruitingNon-segmental VitiligoUnited States, Canada, Australia, Korea, Republic of, Switzerland, Germany, Spain, Chile, France, Israel, Netherlands, Japan, Belgium, Argentina
-
Sun Pharmaceutical Industries LimitedCompletedNon-segmental VitiligoUnited States, India
-
AbbVieCompletedNon-Segmental VitiligoUnited States, Canada, France, Japan
-
St. Luke's-Roosevelt Hospital CenterCompletedVitiligo VulgarisUnited States
-
Incyte CorporationCompletedNon-segmental VitiligoUnited States, Spain, Canada, France, Poland, Bulgaria, Germany, Italy
-
PfizerCompletedActive Non-segmental VitiligoSpain, United States, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, Belgium, Italy
-
University of Massachusetts, WorcesterRecruiting
-
University of Colorado, DenverPfizerActive, not recruiting
-
University of California, IrvineTerminated
-
Tufts Medical CenterCompleted
-
University of Texas Southwestern Medical CenterCompleted
-
John HarrisCompleted
-
Brigham and Women's HospitalBristol-Myers SquibbUnknown
-
Mary Sullivan-WhalenCompleted
-
Medical University of South CarolinaAmerican Skin AssociationActive, not recruiting
-
Dermavant Sciences GmbHCompletedVitiligoUnited States
-
Henry Ford Health SystemM.D. Anderson Cancer CenterCompleted
-
Crown Laboratories, Inc.CompletedVitiligoUnited States
-
Avita MedicalTerminated
-
Icahn School of Medicine at Mount SinaiCelgeneCompleted
-
Henry Ford Health SystemWithdrawn
-
Applied Biology, Inc.Completed
-
Massachusetts General HospitalMomelan TechnologiesTerminated
-
Mimi Cho, MDAmerican Skin AssociationTerminated
-
Clinuvel, Inc.Recruiting
-
Henry Ford Health SystemTerminated
-
Clinuvel, Inc.Recruiting
-
Rutgers, The State University of New JerseyTerminated
-
Medical University of South CarolinaCompleted
-
Momentum DataPfizerCompletedVitiligo | Melanoma (Skin) | Actinic Keratoses | Basal Cell Carcinoma | Squamous Cell Carcinoma | Nonmelanoma Skin CancerUnited Kingdom
-
University of Medicine and Dentistry of New JerseyCompleted
-
Clinuvel Pharmaceuticals LimitedCompleted
-
Aclaris Therapeutics, Inc.Completed